ADAR1’s Big Buy in Tenax Boosts Investor Confidence Amid Volatility
ADAR1 Capital’s steady $2.3 M buy‑in boosts Tenax Therapeutics to 8.5% ownership, signaling institutional confidence amid volatile shares and a promising pulmonary hypertension pipeline.
3 minutes to read